LBL-024 with chemotherapy for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have a confirmed diagnosis of platinum-resistant ovarian cancer.
- Be able to start a new treatment and have recovered from side effects of prior therapies.
- Not be pregnant or breastfeeding, and follow birth control requirements if of childbearing age.
- Not have other serious health conditions or infections that would interfere with participation.
- Be willing to attend all study visits and undergo required tests and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.